MovDisordV3, PascalFrancis, Corpus, bibRecord, 002760

Field validation of a method for population screening of parkinsonism

Identifieur interne : 002760 ( PascalFrancis/Corpus ); précédent : 002759; suivant : 002761

Field validation of a method for population screening of parkinsonism

Auteurs : Maria Dolores Sevillano ; Jesus De Pedro-Cuesta ; Jacinto Duarte ; Luis Erik Claveria

Source :

Movement disorders [ 0885-3185 ] ; 2002.

RBID : Pascal:02-0315698

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Parkinsonisme, Espagne, Dépistage, Méthode, Homme.

English descriptors

KwdEn :
- Human, Medical screening, Method, Parkinson disease, Parkinsonism, Spain.

Abstract

We sought to validate an instrument and two application procedures for screening for prevalence of parkinsonism in conjunction with a door-to-door survey in Cantalejo, Spain. Residents in Cantalejo aged 40 years or older were assigned to three groups specifically designed to optimise case-finding and cost/efficiency. A nine-item questionnaire aimed at identifying parkinsonism-related symptoms was administered and collected door-to-door by laymen and repeated by specialists at a medical facility before neurological examination. Diagnoses were then established and confirmed after a 3-year follow-up. Different indices for and concordance of answers were studied for both applications in groups of 25 individuals with parkinsonism. The scoring procedure was updated using the prevalence community sample of parkinsonism. Whereas the application administered by laymen showed, using the same cut-off scores, a higher sensitivity for parkinsonism than that administered by trained personnel, it yielded a lower positive predictive value for parkinsonism diagnosed during the study, i.e., at a 30-point cut-off (96% vs. 80% and 15% vs. 76%, respectively). Concordance was ≥64% with κ ≥0.316 and P ≤0.031 for six questions. Instrument sensitivity, determined by different cut-off scores, had a high impact on PD detection, observed MIF ratio, severity, and mean age at onset. Choice of screening method or application can considerably affect prevalence measurements and disease natural history parameters described in PD surveys.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 17`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Field validation of a method for population screening of parkinsonism`
A11	`01`	`1`		`@1 SEVILLANO (Maria Dolores)`
A11	`02`	`1`		`@1 DE PEDRO-CUESTA (Jesus)`
A11	`03`	`1`		`@1 DUARTE (Jacinto)`
A11	`04`	`1`		`@1 CLAVERIA (Luis Erik)`
A14	`01`			`@1 Department of Applied Epidemiology, National Centre for Epidemiology, Carlos III Institute of Public Health @2 Madrid @3 ESP @Z 1 aut. @Z 2 aut.`
A14	`02`			`@1 NEUROTEC, Division of Neurology, Huddinge University Hospital, Karolinska Institute @2 Huddinge @3 SWE @Z 2 aut.`
A14	`03`			`@1 Department of Neurology, Segovia General Hospital @2 Segovia @3 ESP @Z 3 aut. @Z 4 aut.`
A20				`@1 258-264`
A21				`@1 2002`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000100907450050`
A44				`@0 0000 @1 © 2002 INIST-CNRS. All rights reserved.`
A45				`@0 25 ref.`
A47	`01`	`1`		`@0 02-0315698`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 We sought to validate an instrument and two application procedures for screening for prevalence of parkinsonism in conjunction with a door-to-door survey in Cantalejo, Spain. Residents in Cantalejo aged 40 years or older were assigned to three groups specifically designed to optimise case-finding and cost/efficiency. A nine-item questionnaire aimed at identifying parkinsonism-related symptoms was administered and collected door-to-door by laymen and repeated by specialists at a medical facility before neurological examination. Diagnoses were then established and confirmed after a 3-year follow-up. Different indices for and concordance of answers were studied for both applications in groups of 25 individuals with parkinsonism. The scoring procedure was updated using the prevalence community sample of parkinsonism. Whereas the application administered by laymen showed, using the same cut-off scores, a higher sensitivity for parkinsonism than that administered by trained personnel, it yielded a lower positive predictive value for parkinsonism diagnosed during the study, i.e., at a 30-point cut-off (96% vs. 80% and 15% vs. 76%, respectively). Concordance was ≥64% with κ ≥0.316 and P ≤0.031 for six questions. Instrument sensitivity, determined by different cut-off scores, had a high impact on PD detection, observed MIF ratio, severity, and mean age at onset. Choice of screening method or application can considerably affect prevalence measurements and disease natural history parameters described in PD surveys.
C02	`01`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinsonisme @2 NM @5 04`
C03	`02`	`X`	`ENG`	`@0 Parkinsonism @2 NM @5 04`
C03	`02`	`X`	`SPA`	`@0 Parkinson síndrome @2 NM @5 04`
C03	`03`	`X`	`FRE`	`@0 Espagne @2 NG @5 16`
C03	`03`	`X`	`ENG`	`@0 Spain @2 NG @5 16`
C03	`03`	`X`	`SPA`	`@0 España @2 NG @5 16`
C03	`04`	`X`	`FRE`	`@0 Dépistage @5 17`
C03	`04`	`X`	`ENG`	`@0 Medical screening @5 17`
C03	`04`	`X`	`SPA`	`@0 Descubrimiento @5 17`
C03	`05`	`X`	`FRE`	`@0 Méthode @5 18`
C03	`05`	`X`	`ENG`	`@0 Method @5 18`
C03	`05`	`X`	`SPA`	`@0 Método @5 18`
C03	`06`	`X`	`FRE`	`@0 Homme @5 20`
C03	`06`	`X`	`ENG`	`@0 Human @5 20`
C03	`06`	`X`	`SPA`	`@0 Hombre @5 20`
C07	`01`	`X`	`FRE`	`@0 Europe @2 NG`
C07	`01`	`X`	`ENG`	`@0 Europe @2 NG`
C07	`01`	`X`	`SPA`	`@0 Europa @2 NG`
C07	`02`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`03`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`03`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`03`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`04`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`05`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`06`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`06`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`06`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
N21				`@1 175`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 02-0315698 INIST
ET :	Field validation of a method for population screening of parkinsonism
AU :	SEVILLANO (Maria Dolores); DE PEDRO-CUESTA (Jesus); DUARTE (Jacinto); CLAVERIA (Luis Erik)
AF :	Department of Applied Epidemiology, National Centre for Epidemiology, Carlos III Institute of Public Health/Madrid/Espagne (1 aut., 2 aut.); NEUROTEC, Division of Neurology, Huddinge University Hospital, Karolinska Institute/Huddinge/Suède (2 aut.); Department of Neurology, Segovia General Hospital/Segovia/Espagne (3 aut., 4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 2; Pp. 258-264; Bibl. 25 ref.
LA :	Anglais
EA :	We sought to validate an instrument and two application procedures for screening for prevalence of parkinsonism in conjunction with a door-to-door survey in Cantalejo, Spain. Residents in Cantalejo aged 40 years or older were assigned to three groups specifically designed to optimise case-finding and cost/efficiency. A nine-item questionnaire aimed at identifying parkinsonism-related symptoms was administered and collected door-to-door by laymen and repeated by specialists at a medical facility before neurological examination. Diagnoses were then established and confirmed after a 3-year follow-up. Different indices for and concordance of answers were studied for both applications in groups of 25 individuals with parkinsonism. The scoring procedure was updated using the prevalence community sample of parkinsonism. Whereas the application administered by laymen showed, using the same cut-off scores, a higher sensitivity for parkinsonism than that administered by trained personnel, it yielded a lower positive predictive value for parkinsonism diagnosed during the study, i.e., at a 30-point cut-off (96% vs. 80% and 15% vs. 76%, respectively). Concordance was ≥64% with κ ≥0.316 and P ≤0.031 for six questions. Instrument sensitivity, determined by different cut-off scores, had a high impact on PD detection, observed MIF ratio, severity, and mean age at onset. Choice of screening method or application can considerably affect prevalence measurements and disease natural history parameters described in PD surveys.
CC :	002B17G
FD :	Parkinson maladie; Parkinsonisme; Espagne; Dépistage; Méthode; Homme
FG :	Europe; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative
ED :	Parkinson disease; Parkinsonism; Spain; Medical screening; Method; Human
EG :	Europe; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease
SD :	Parkinson enfermedad; Parkinson síndrome; España; Descubrimiento; Método; Hombre
LO :	INIST-20953.354000100907450050
ID :	02-0315698

Links to Exploration step

Pascal:02-0315698

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Field validation of a method for population screening of parkinsonism</title>
<author><name sortKey="Sevillano, Maria Dolores" sort="Sevillano, Maria Dolores" uniqKey="Sevillano M" first="Maria Dolores" last="Sevillano">Maria Dolores Sevillano</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Applied Epidemiology, National Centre for Epidemiology, Carlos III Institute of Public Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Pedro Cuesta, Jesus" sort="De Pedro Cuesta, Jesus" uniqKey="De Pedro Cuesta J" first="Jesus" last="De Pedro-Cuesta">Jesus De Pedro-Cuesta</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Applied Epidemiology, National Centre for Epidemiology, Carlos III Institute of Public Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>NEUROTEC, Division of Neurology, Huddinge University Hospital, Karolinska Institute</s1>
<s2>Huddinge</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Duarte, Jacinto" sort="Duarte, Jacinto" uniqKey="Duarte J" first="Jacinto" last="Duarte">Jacinto Duarte</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Segovia General Hospital</s1>
<s2>Segovia</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Claveria, Luis Erik" sort="Claveria, Luis Erik" uniqKey="Claveria L" first="Luis Erik" last="Claveria">Luis Erik Claveria</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Segovia General Hospital</s1>
<s2>Segovia</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0315698</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0315698 INIST</idno>
<idno type="RBID">Pascal:02-0315698</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002760</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Field validation of a method for population screening of parkinsonism</title>
<author><name sortKey="Sevillano, Maria Dolores" sort="Sevillano, Maria Dolores" uniqKey="Sevillano M" first="Maria Dolores" last="Sevillano">Maria Dolores Sevillano</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Applied Epidemiology, National Centre for Epidemiology, Carlos III Institute of Public Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Pedro Cuesta, Jesus" sort="De Pedro Cuesta, Jesus" uniqKey="De Pedro Cuesta J" first="Jesus" last="De Pedro-Cuesta">Jesus De Pedro-Cuesta</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Applied Epidemiology, National Centre for Epidemiology, Carlos III Institute of Public Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>NEUROTEC, Division of Neurology, Huddinge University Hospital, Karolinska Institute</s1>
<s2>Huddinge</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Duarte, Jacinto" sort="Duarte, Jacinto" uniqKey="Duarte J" first="Jacinto" last="Duarte">Jacinto Duarte</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Segovia General Hospital</s1>
<s2>Segovia</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Claveria, Luis Erik" sort="Claveria, Luis Erik" uniqKey="Claveria L" first="Luis Erik" last="Claveria">Luis Erik Claveria</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Segovia General Hospital</s1>
<s2>Segovia</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Human</term>
<term>Medical screening</term>
<term>Method</term>
<term>Parkinson disease</term>
<term>Parkinsonism</term>
<term>Spain</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Parkinsonisme</term>
<term>Espagne</term>
<term>Dépistage</term>
<term>Méthode</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We sought to validate an instrument and two application procedures for screening for prevalence of parkinsonism in conjunction with a door-to-door survey in Cantalejo, Spain. Residents in Cantalejo aged 40 years or older were assigned to three groups specifically designed to optimise case-finding and cost/efficiency. A nine-item questionnaire aimed at identifying parkinsonism-related symptoms was administered and collected door-to-door by laymen and repeated by specialists at a medical facility before neurological examination. Diagnoses were then established and confirmed after a 3-year follow-up. Different indices for and concordance of answers were studied for both applications in groups of 25 individuals with parkinsonism. The scoring procedure was updated using the prevalence community sample of parkinsonism. Whereas the application administered by laymen showed, using the same cut-off scores, a higher sensitivity for parkinsonism than that administered by trained personnel, it yielded a lower positive predictive value for parkinsonism diagnosed during the study, i.e., at a 30-point cut-off (96% vs. 80% and 15% vs. 76%, respectively). Concordance was ≥64% with κ ≥0.316 and P ≤0.031 for six questions. Instrument sensitivity, determined by different cut-off scores, had a high impact on PD detection, observed MIF ratio, severity, and mean age at onset. Choice of screening method or application can considerably affect prevalence measurements and disease natural history parameters described in PD surveys.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>17</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Field validation of a method for population screening of parkinsonism</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SEVILLANO (Maria Dolores)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DE PEDRO-CUESTA (Jesus)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DUARTE (Jacinto)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CLAVERIA (Luis Erik)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Applied Epidemiology, National Centre for Epidemiology, Carlos III Institute of Public Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>NEUROTEC, Division of Neurology, Huddinge University Hospital, Karolinska Institute</s1>
<s2>Huddinge</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, Segovia General Hospital</s1>
<s2>Segovia</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>258-264</s1>
</fA20>
<fA21><s1>2002</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000100907450050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>25 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0315698</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We sought to validate an instrument and two application procedures for screening for prevalence of parkinsonism in conjunction with a door-to-door survey in Cantalejo, Spain. Residents in Cantalejo aged 40 years or older were assigned to three groups specifically designed to optimise case-finding and cost/efficiency. A nine-item questionnaire aimed at identifying parkinsonism-related symptoms was administered and collected door-to-door by laymen and repeated by specialists at a medical facility before neurological examination. Diagnoses were then established and confirmed after a 3-year follow-up. Different indices for and concordance of answers were studied for both applications in groups of 25 individuals with parkinsonism. The scoring procedure was updated using the prevalence community sample of parkinsonism. Whereas the application administered by laymen showed, using the same cut-off scores, a higher sensitivity for parkinsonism than that administered by trained personnel, it yielded a lower positive predictive value for parkinsonism diagnosed during the study, i.e., at a 30-point cut-off (96% vs. 80% and 15% vs. 76%, respectively). Concordance was ≥64% with κ ≥0.316 and P ≤0.031 for six questions. Instrument sensitivity, determined by different cut-off scores, had a high impact on PD detection, observed MIF ratio, severity, and mean age at onset. Choice of screening method or application can considerably affect prevalence measurements and disease natural history parameters described in PD surveys.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinsonisme</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinsonism</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson síndrome</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Espagne</s0>
<s2>NG</s2>
<s5>16</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Spain</s0>
<s2>NG</s2>
<s5>16</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>España</s0>
<s2>NG</s2>
<s5>16</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dépistage</s0>
<s5>17</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Medical screening</s0>
<s5>17</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Descubrimiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Méthode</s0>
<s5>18</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Method</s0>
<s5>18</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Método</s0>
<s5>18</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Europe</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Europe</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Europa</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>175</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 02-0315698 INIST</NO>
<ET>Field validation of a method for population screening of parkinsonism</ET>
<AU>SEVILLANO (Maria Dolores); DE PEDRO-CUESTA (Jesus); DUARTE (Jacinto); CLAVERIA (Luis Erik)</AU>
<AF>Department of Applied Epidemiology, National Centre for Epidemiology, Carlos III Institute of Public Health/Madrid/Espagne (1 aut., 2 aut.); NEUROTEC, Division of Neurology, Huddinge University Hospital, Karolinska Institute/Huddinge/Suède (2 aut.); Department of Neurology, Segovia General Hospital/Segovia/Espagne (3 aut., 4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 2; Pp. 258-264; Bibl. 25 ref.</SO>
<LA>Anglais</LA>
<EA>We sought to validate an instrument and two application procedures for screening for prevalence of parkinsonism in conjunction with a door-to-door survey in Cantalejo, Spain. Residents in Cantalejo aged 40 years or older were assigned to three groups specifically designed to optimise case-finding and cost/efficiency. A nine-item questionnaire aimed at identifying parkinsonism-related symptoms was administered and collected door-to-door by laymen and repeated by specialists at a medical facility before neurological examination. Diagnoses were then established and confirmed after a 3-year follow-up. Different indices for and concordance of answers were studied for both applications in groups of 25 individuals with parkinsonism. The scoring procedure was updated using the prevalence community sample of parkinsonism. Whereas the application administered by laymen showed, using the same cut-off scores, a higher sensitivity for parkinsonism than that administered by trained personnel, it yielded a lower positive predictive value for parkinsonism diagnosed during the study, i.e., at a 30-point cut-off (96% vs. 80% and 15% vs. 76%, respectively). Concordance was ≥64% with κ ≥0.316 and P ≤0.031 for six questions. Instrument sensitivity, determined by different cut-off scores, had a high impact on PD detection, observed MIF ratio, severity, and mean age at onset. Choice of screening method or application can considerably affect prevalence measurements and disease natural history parameters described in PD surveys.</EA>
<CC>002B17G</CC>
<FD>Parkinson maladie; Parkinsonisme; Espagne; Dépistage; Méthode; Homme</FD>
<FG>Europe; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Parkinsonism; Spain; Medical screening; Method; Human</ED>
<EG>Europe; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<SD>Parkinson enfermedad; Parkinson síndrome; España; Descubrimiento; Método; Hombre</SD>
<LO>INIST-20953.354000100907450050</LO>
<ID>02-0315698</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002760 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002760 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:02-0315698
   |texte=   Field validation of a method for population screening of parkinsonism
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Field validation of a method for population screening of parkinsonism

Field validation of a method for population screening of parkinsonism

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri